Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Consequences Escalate If Firms Ignore GMP Compliance Issues

This article was originally published in The Tan Sheet

Executive Summary

A warning letter is a firm’s last “real chance” to correct GMP violations without winding up in court, but not the only chance, says FDA attorney Annamarie Kempic. She outlines factors the agency weighs when considering enforcement actions.

You may also be interested in...



J&J Prioritizes OTC Return With McNeil Remediation End In Sight

Johnson & Johnson CEO Alex Gorsky says bringing recalled OTCs such as Tylenol and Motrin products back to market is the firm’s “clear number one priority” in the near term. J&J also has a timetable for completing its responsibilities under a consent decree with FDA in place since 2011.

CHD/barley

Separately, the agency announced in the FR that it is adopting as a final rule a January amendment to the CHD/dietary fiber health claim, which named barley as an additional source of beta-glucan soluble fiber (1"The Tan Sheet" Jan. 2, 2006, In Brief)...

J&J Consumer Sales Slip Even As Recalled Brands, Seasonal Items Reach Stores

J&J reports worldwide consumer sales dipped 0.6% to $3.6 billion despite retailers buying more upper respiratory and analgesic products to prepare for the cough and cold season. But in key OTC categories the firm is regaining market share it lost when its iconic brands were temporarily not available.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1133990

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel